Stuart Therapeutics Spotlights Topical RP Program - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

  • By

  • Eric Schlumpf

  • July 15, 2026

  • 2 min

Share

Objective:

To discuss a new inherited retinal disease program based on a collagen mimetic peptide platform for retinitis pigmentosa.

Approach:
  • Program Overview: The program is designed as a topical therapy for retinitis pigmentosa, focusing on safety and efficacy for younger patients.
  • Mechanism of Action: The therapy aims to provide neuroprotective effects, reduce inflammation, and improve the health of the posterior retina.
  • Preclinical Studies: New data from preclinical studies in nonhuman primates show effective topical drop penetration throughout the posterior retina.
Key Findings:
  • The topical therapy demonstrates penetration into the critical retinal extracellular matrix region.
  • The program is in preclinical development stages.
Interpretation:

Conclusion:

Original Source(s)

Stuart Therapeutics Spotlights Topical RP Program

  • by Eric Schlumpf

  • July 15, 2026

Related Content

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Floaters May Signal Higher Risk Than Flashes

New study examines retinal detachment risk in primary care presentations

Could Red-Light Therapy Change Myopia Care? 

Across 28 trials, pediatric patients receiving therapy had less myopia progression over 12 months, though long-term risks remain under study.